Premium
Risk of cutaneous T‐cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non‐Hodgkin lymphoma
Author(s) -
Chang Timothy W.,
Weaver Amy L.,
Shanafelt Tait D.,
Habermann Thomas M.,
Wriston Cooper C.,
Cerhan James R.,
Call Timothy G.,
Brewer Jerry D.
Publication year - 2017
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/ijd.13653
Subject(s) - medicine , chronic lymphocytic leukemia , incidence (geometry) , lymphoma , epidemiology , leukemia , mycosis fungoides , aggressive lymphoma , gastroenterology , oncology , immunology , rituximab , physics , optics
Background Second hematologic cancers in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL ) are well documented and include Hodgkin lymphoma, therapy‐related acute myeloid leukemia/myelodysplastic syndromes, and transformation to diffuse large B‐cell lymphoma. Although cutaneous T‐cell lymphoma ( CTCL ) has been reported in patients with CLL , the incidence and comparison to expected rates are unknown. We evaluated the incidence of CTCL among patients with CLL or other non‐Hodgkin lymphoma ( NHL ) subtypes using data from the Surveillance, Epidemiology, and End Results ( SEER ) Program. Methods We searched the SEER 13 registries for patients with a diagnosis of CLL and NHL between 1992 and 2008. Among patients identified, we evaluated the incidence of CTCL . Results Among 31,286 patients with CLL , the incidence of CTCL was not significantly higher in men than women: 104.2 (95% CI , 50.0–191.8) and 28.1 (95% CI , 3.4–101.3) per 1,000,000 person‐years, respectively ( P = 0.06). Among 97,691 patients with NHL , the incidence of CTCL was similar in men and women (97.9 [95% CI , 62.0–146.9] and 92.0 [95% CI , 56.2–142.1] per 1,000,000 person‐years, respectively; P = 0.84). The incidence of CTCL among males with CLL (standardized incidence ratio [SIR], 3.0 [95% CI , 1.4–5.5]), males with NHL ( SIR , 3.7 [95% CI , 2.3–5.5]), and females with NHL ( SIR , 5.9 [95% CI , 3.6–9.1]) was significantly higher than expected in the general population (all P < 0.001). Conclusion The risk of CTCL is greater in men with CLL than in the general population. In patients with NHL , both men and women are at greater risk for CTCL than in the general population.